变构调节
激酶
药物发现
磷酸化
蛋白激酶A
生物化学
化学
药理学
生物
酶
作者
Xiaohong Shu,Jian Zhang,Yutong Hu
出处
期刊:Zhongguo kexue
[Science China Press]
日期:2015-09-01
卷期号:45 (9): 884-891
标识
DOI:10.1360/n032015-00067
摘要
Protein kinases are protein phosphokinases that modify other proteins by chemically adding phosphate groups on their residues (phosphorylation). Aberrant activity of protein kinases usually results in tumor growth and metastasis, and then protein kinases has been one of the most significant research areas in the design and development of novel anticancer drugs. Currently one kinase allosteric drug has been approved by the US Food and Drug Administration. Kinase allosteric drugs possess several distinct advantages over ATP competitive drugs that bind to the same kinases, including higher selectivity, lower toxicity, slow kinetics as well as less side effects. The development of kinase allosteric drugs appears to be a promising new trend in drug discovery. Given the immense advantages of kinase allosteric modulators in cancer therapy, this review focuses on the progress in allosteric modulators of protein kinases.
科研通智能强力驱动
Strongly Powered by AbleSci AI